{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:51:37Z","timestamp":1777441897091,"version":"3.51.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"BMS"},{"name":"Gilead Science"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.cld.2017.03.015","type":"journal-article","created":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T00:31:24Z","timestamp":1499473884000},"page":"631-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Treatment of Extrahepatic Manifestations of Hepatitis C Virus"],"prefix":"10.1016","volume":"21","author":[{"given":"Elisabetta","family":"Degasperi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2017.03.015_bib1","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2017.03.015_bib2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/liv.13071","article-title":"Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis","volume":"36","author":"Tada","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2017.03.015_bib3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cld.2017.03.015_bib4","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1002\/art.10699","article-title":"Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis","volume":"46","author":"Cacoub","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cld.2017.03.015_bib5","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1002\/art.22168","article-title":"Antiviral therapy for hepatitis C virus\u2013associated mixed cryoglobulinemia vasculitis: a long-term follow up study","volume":"54","author":"Saadoun","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cld.2017.03.015_bib6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2009-10-248518","article-title":"Rituximab plus Peg-interferon-alpha\/ribavirin compared with Peg-interferon-alpha\/ribavirin in hepatitis C-related mixed cryoglobulinemia","volume":"116","author":"Saadoun","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cld.2017.03.015_bib7","first-page":"933","article-title":"Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study","volume":"29","author":"Mazzaro","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cld.2017.03.015_bib8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s12072-011-9303-x","article-title":"Hepatitis C virus (genotype 4)-associated mixed cryoglobulinemia vasculitis: effects of antiviral treatment","volume":"6","author":"El Khayat","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cld.2017.03.015_bib9","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.27623","article-title":"Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study","volume":"61","author":"Gragnani","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.03.015_bib10","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2007-09-112490","article-title":"Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia","volume":"111","author":"Giannini","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cld.2017.03.015_bib11","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.dld.2014.05.017","article-title":"Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study","volume":"46","author":"Gragnani","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cld.2017.03.015_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2014.08.015","article-title":"PegIFN\u03b1\/ribavirin\/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis","volume":"62","author":"Saadoun","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2017.03.015_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcv.2015.09.003","article-title":"Successful treatment of HCV-associated cryoglobulinemia with ombitasvir\/paritaprevir\/ritonavir, dasabuvir and ribavirin: a case report","volume":"72","author":"Makara","year":"2015","journal-title":"J\u00a0Clin Virol"},{"issue":"4","key":"10.1016\/j.cld.2017.03.015_bib14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2016.09.158","article-title":"Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals","volume":"15","author":"Bonacci","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2017.03.015_bib15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.03.015_bib16","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"64","author":"Gragnani","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.03.015_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/00325481.2015.1021660","article-title":"Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a case series","volume":"127","author":"Cornella","year":"2015","journal-title":"Postgrad Med"},{"key":"10.1016\/j.cld.2017.03.015_bib18","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/art.24703","article-title":"Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients","volume":"60","author":"Terrier","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cld.2017.03.015_bib19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","article-title":"Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study","volume":"116","author":"Dammacco","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cld.2017.03.015_bib20","doi-asserted-by":"crossref","first-page":"816424","DOI":"10.1155\/2015\/816424","article-title":"Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy","volume":"2015","author":"Urraro","year":"2015","journal-title":"Case Reports Immunol"},{"key":"10.1016\/j.cld.2017.03.015_bib21","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.amjmed.2007.06.022","article-title":"Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C","volume":"120","author":"Kawamura","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.cld.2017.03.015_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2017.03.015_bib23","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood.V97.6.1555","article-title":"The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection","volume":"97","author":"Zuckerman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cld.2017.03.015_bib24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7326\/0003-4819-137-7-200210010-00008","article-title":"Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas","volume":"137","author":"Zignego","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2017.03.015_bib25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2005.06.008","article-title":"Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience","volume":"23","author":"Vallisa","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cld.2017.03.015_bib26","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/sj.leu.2403443","article-title":"Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas","volume":"18","author":"Kelaidi","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.cld.2017.03.015_bib27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2008.07565.x","article-title":"Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas","volume":"145","author":"Mazzaro","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cld.2017.03.015_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood-2004-05-1711","article-title":"Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?","volume":"105","author":"Saadoun","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cld.2017.03.015_bib29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4254\/wjh.v3.i11.278","article-title":"Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma","volume":"3","author":"Pellicelli","year":"2011","journal-title":"World J Hepatol"},{"key":"10.1016\/j.cld.2017.03.015_bib30","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi","volume":"25","author":"Arcaini","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cld.2017.03.015_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ajh.23889","article-title":"Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study","volume":"90","author":"Michot","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cld.2017.03.015_bib32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jhep.2008.06.025","article-title":"Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma","volume":"49","author":"La Mura","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2017.03.015_bib33","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/ijc.30372","article-title":"Antiviral therapy improves overall survival in hepatitis C virus infected patients who develop diffuse large B-cell lymphoma","volume":"139","author":"Hosry","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cld.2017.03.015_bib34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jhep.2014.09.031","article-title":"Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3\/NS4A inhibitor-based treatment. A case report","volume":"62","author":"Rossotti","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2017.03.015_bib35","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/liv.12897","article-title":"HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents","volume":"35","author":"Carrier","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2017.03.015_bib36","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"128","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cld.2017.03.015_bib37","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1053\/j.ajkd.2003.11.020","article-title":"Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN","volume":"43","author":"Alric","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cld.2017.03.015_bib38","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2015-208339","article-title":"Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study","volume":"75","author":"Saadoun","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cld.2017.03.015_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2017.03.015_bib40","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/liv.13123","article-title":"The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment","volume":"36","author":"De Nicola","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2017.03.015_bib41","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.cld.2017.03.015_bib42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2017.03.015_bib43","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2017.03.015_bib44","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2017.03.015_bib45","article-title":"EXPEDITION-4: efficacy and safety of Glecaprevir\/Pibrentasvir (ABT-493\/ABT-530) in patients with renal impairment and chronic hepatitis C virus genotype 1-6 infection","author":"Gane","year":"2016","journal-title":"Abstract presented at the AASLD Liver Meeting"},{"issue":"2","key":"10.1016\/j.cld.2017.03.015_bib46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with ledipasvir-sofosbuvir for 12 or 24\u00a0weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial","volume":"166","author":"Colombo","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2017.03.015_bib47","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jhep.2007.11.022","article-title":"Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C","volume":"48","author":"Romero-G\u00f3mez","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2017.03.015_bib48","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/hep.22703","article-title":"Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C","volume":"49","author":"Arase","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.03.015_bib49","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/hep.25867","article-title":"Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C","volume":"56","author":"Aghemo","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.03.015_bib50","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","article-title":"Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.03.015_bib51","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2017.03.015_bib52","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jhep.2012.06.030","article-title":"Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study","volume":"57","author":"Sarkar","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2017.03.015_bib53","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.20659","article-title":"Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment","volume":"41","author":"Spiegel","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2017.03.015_bib54","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clpt.2004.09.007","article-title":"Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin","volume":"77","author":"Kraus","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cld.2017.03.015_bib55","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1468-1293.2007.00505.x","article-title":"Improved cognitive function as a consequence of hepatitis C virus treatment","volume":"8","author":"Thein","year":"2007","journal-title":"HIV Med"},{"key":"10.1016\/j.cld.2017.03.015_bib56","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2011.09.015","article-title":"Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition","volume":"56","author":"Byrnes","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2017.03.015_bib57","first-page":"237","article-title":"Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C","volume":"15","author":"Nagao","year":"2005","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.cld.2017.03.015_bib58","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000247552","article-title":"Lichen planus and virus C hepatitis: disappearance of the lichen under interferon alfa therapy","volume":"184","author":"Doutre","year":"1992","journal-title":"Dermatology"},{"key":"10.1016\/j.cld.2017.03.015_bib59","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1038\/ctg.2016.37","article-title":"Successful treatment of hepatitis C virus-associated oral lichen planus by interferon-free therapy with direct-acting antivirals","volume":"7","author":"Nagao","year":"2016","journal-title":"Clin Transl Gastroenterol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326117300326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326117300326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T23:44:45Z","timestamp":1537227885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326117300326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1089326117300326"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2017.03.015","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Extrahepatic Manifestations of Hepatitis C Virus","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2017.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}